<DOC>
	<DOCNO>NCT01120223</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy daily use LEO 80185 gel adolescent subject ( age 12 17 ) scalp psoriasis . LEO 80185 gel marketing approval many country brand name Xamiol® gel Taclonex Scalp® Topical Suspension treatment scalp psoriasis adult . No study perform subject young 18 year</brief_summary>
	<brief_title>Safety Efficacy LEO 80185 Gel Adolescent Subjects ( Aged 12 17 ) With Scalp Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>A clinical diagnosis scalp psoriasis extent equal 10 % scalp area A clinical diagnosis scalp psoriasis least moderate severity accord investigator 's global assessment Serum albumincorrected calcium upper reference limit screen visit 2 A history hypersensitivity component LEO 80185 gel Topical treatment trunk and/or limbs potent ( WHO group IV ) corticosteroid within 2 week prior Visit 1 study Topical treatment face and/or genital/skin fold potent potent ( WHO group IIIIV ) corticosteroid within 2 week prior Visit 1 study Systemic treatment biological therapy ( market market ) , possible effect scalp psoriasis within follow time period prior Visit 1 study : etanercept within 4 week prior Visit 1 adalimumab , alefacept , infliximab within 2 month prior Visit 1 ustekinumab within 4 month prior Visit 1 experimental product within 4 weeks/5 halflives ( whichever longer ) prior Visit 1 Systemic treatment therapy biologicals , possible effect scalp psoriasis ( e.g. , corticosteroid , retinoids , immunosuppressant , PUVA ) within 4 week prior Visit 1 ( Day 0 ) study UVB therapy within 2 week prior Visit 1 study Any topical treatment scalp ( except emollient nonsteroid medicate shampoo ) within 2 week prior Visit 1 study Systemic calcium vitamin D supplement , antacid , diuretic , antiepileptic , diphosphonates calcitonin within 4 week prior screen visit 2 study Planned initiation , change , concomitant medication could affect scalp psoriasis ( e.g. , betablockers , chloroquine , lithium , ACE inhibitor ) study Current diagnosis guttate , erythrodermic , exfoliative pustular psoriasis Subjects follow condition present scalp area : viral ( e.g. , herpes varicella ) lesion skin , fungal bacterial skin infection , parasitic infection , skin manifestation relation syphilis tuberculosis , rosacea , acne vulgaris , acne rosacea , atrophic skin , stria atrophicae , fragility skin vein , ichthyosis , ulcer wound Planned excessive exposure sun study may affect scalp psoriasis Known suspect disorder calcium metabolism associate hypercalcaemia</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>